Protein

Gwangju Institute of Science and Technology Researchers Develop a Tool for Studying Inflammatory Diseases Related to COVID-19

Retrieved on: 
Tuesday, May 17, 2022 - 1:37pm

GWANGJU, South Korea, May 17, 2022 /PRNewswire/ -- The SARS-CoV-2, or the novel coronavirus, has affected more than 500 million people worldwide. Apart from the symptoms associated with COVID-19 infection, it has recently been reported that the virus also leads to a subsequent development of autoimmune diseases in patients.

Key Points: 
  • Autoimmune diseases like rheumatoid arthritis, lupus, or multi-inflammatory syndromes arise when the immune system confuses healthy cells with pathogens and starts attacking them.
  • To this end, a team of researchers from the Gwangju Institute of Science and Technology (GIST) led by Prof. Jihwan Park developed a new bioinformatics pipeline.
  • The team hopes their new tool will facilitate comparison between studies, providing a robust framework for further investigation on molecular mimicry and autoimmune diseases.
  • "Although autoimmune diseases affect less than 10% of the population, studying them is important since it severely impacts the quality of life.

Glympse Appoints Jonathan Wilde, Ph.D., as Chief Scientific Officer to Advance Biosensor Assay Platform

Retrieved on: 
Tuesday, May 17, 2022 - 1:00pm

CAMBRIDGE, Mass., May 17, 2022 /PRNewswire/ --Glympse, a biotechnology company developing revolutionary technology to diagnose and monitor disease, today announced the appointment of Jonathan Wilde, Ph.D., as Chief Scientific Officer.

Key Points: 
  • CAMBRIDGE, Mass., May 17, 2022 /PRNewswire/ --Glympse, a biotechnology company developing revolutionary technology to diagnose and monitor disease, today announced the appointment of Jonathan Wilde, Ph.D., as Chief Scientific Officer.
  • Dr. Wilde brings extensive experience in the development and launch of molecular-based diagnostics to Glympse as the company expands development of its protein activity biosensor assay platform.
  • "Jon brings a wealth of experience and strong track record in the field of late-stage molecular diagnostic development," said Caroline Loew, Ph.D., Chief Executive Officer of Glympse.
  • Using proprietary machine learning algorithms, the Glympse biosensor protease activity assay data is used to generate real-time information about the disease.

Global Oral Biologics & Biosimilar Drugs Markets, 2016-2021, 2021-2026F, 2031F: Lymphocyte Modulators, Interleukin Inhibitors, & Tumor Necrosis Factor-Alpha Inhibitors - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 17, 2022 - 12:47pm

Oral Biologics & Biosimilar Drugs Implants Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global oral biologics & biosimilars market.

Key Points: 
  • Oral Biologics & Biosimilar Drugs Implants Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global oral biologics & biosimilars market.
  • The oral biologics and biosimilar market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, cancer.
  • The oral biologics and biosimilar market comprise of biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer's, multiple sclerosis, HIV/AIDS and other serious conditions.
  • The main therapy types of are oral biologics and biosimilar lymphocyte modulators, interleukin inhibitors and tumor necrosis factor-alpha inhibitors.

Global Gastrointestinal Drugs Market Report 2022: Focus on Antacids, Antiulcerants, Antiobesity, Antiemetics and Antinauseants, & Antidiarrhoeals - Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 17, 2022 - 12:30pm

The global gastrointestinal drugs market is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%.

Key Points: 
  • The global gastrointestinal drugs market is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%.
  • The gastrointestinal drugs market consists of sales of gastrointestinal drugs by entities (organizations, sole traders and partnerships) that produce gastrointestinal drugs to treat gastrointestinal diseases such as ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome.
  • The main types of gastrointestinal drugs are antacids, antiulcerants, antiobesity, antiemetics and antinauseants and antidiarrhoeals.
  • During the forecast period, the growth of the gastrointestinal drugs market will be restrained by patent expiration of branded gastrointestinal drugs.

Civetta Therapeutics Appoints Jesse Smith, Ph.D. as CSO and Susan Ashwell, Ph.D. as SVP of Chemistry

Retrieved on: 
Tuesday, May 17, 2022 - 12:00pm

Its an exciting time for the company as we move toward the clinic, and Jesse and Sue bring tremendous translational drug development experience across multiple therapeutic areas.

Key Points: 
  • Its an exciting time for the company as we move toward the clinic, and Jesse and Sue bring tremendous translational drug development experience across multiple therapeutic areas.
  • They, like others on the Civetta leadership team, have firsthand experience leading programs into the clinic and beyond.
  • Jesse Smith, Ph.D., has over 20 years of experience advancing novel science, drug discovery, and therapeutics across the biotech and pharma industry.
  • Civetta is a biotechnology company focused on the development of therapies that target beta-propeller domains to treat cancer and other diseases.

Codiak Presents New Preclinical Data at ASGCT 2022 on Exosome-Based Strategy to Enhance AAV Gene Therapy

Retrieved on: 
Tuesday, May 17, 2022 - 12:00pm

These data show the power of our engineering platform to enable exosome delivery of AAV as a therapeutic and the potential of this approach to address key limitations associated with AAV gene therapy currently, said Sriram Sathyanarayanan, Ph.D., Chief Scientific Officer, Codiak.

Key Points: 
  • These data show the power of our engineering platform to enable exosome delivery of AAV as a therapeutic and the potential of this approach to address key limitations associated with AAV gene therapy currently, said Sriram Sathyanarayanan, Ph.D., Chief Scientific Officer, Codiak.
  • We have identified the engineering methods and multiple exosome constructs that effectively catch AAV capsids and release them to cells, resulting in highly efficient transduction in vitro.
  • Encapsulation of AAV within exosomes (engEx-AAV) represents a strategy to protect AAV from antibody-mediated neutralization and efficiently deliver AAV to specific cell types, leading to higher potency and lower systemic exposure.
  • The data presented at ASGCT describe the identification and characterization of engEx-AAV constructs engineered to increase AAV yield while retaining desired functionality.

Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas

Retrieved on: 
Tuesday, May 17, 2022 - 12:00pm

Nurix is conducting the open-label, dose escalation and expansion trial at multiple centers in the United Kingdom.

Key Points: 
  • Nurix is conducting the open-label, dose escalation and expansion trial at multiple centers in the United Kingdom.
  • The trial is designed to evaluate the safety and tolerability of NX-5948 in adults with relapsed or refractory B-cell malignancies.
  • Brown, M.D., executive vice president of clinical development of Nurix.
  • NX-5948 has the potential to offer a differentiated clinical profile for patients with relapsed or refractory B cell malignancies.

DGAP-News: Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell replacement therapy to advance a 'functional cure' for diabetes

Retrieved on: 
Tuesday, May 17, 2022 - 7:03am

Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry.

Key Points: 
  • Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry.
  • The Cell Pouch, as part of the Cell Pouch System, is a proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells.
  • In the type 1 form of diabetes (T1D), beta cells are destroyed by the patients own immune system.
  • Furthermore, beta cell replacement therapy also has the potential to prevent or reverse the decline in beta cell function in type 2 diabetes.

GOOD Meat & ADM Partner to Accelerate Cultivated Meat Production

Retrieved on: 
Tuesday, May 17, 2022 - 5:46am

As part of the agreement, ADM will build upon GOOD Meats foundational work to optimize the nutrients needed to enable the growth of the cells .

Key Points: 
  • As part of the agreement, ADM will build upon GOOD Meats foundational work to optimize the nutrients needed to enable the growth of the cells .
  • The companies will also collaborate on product development projects for GOOD Meats pioneering cultivated meat products, starting with chicken.
  • ADMs breadth, depth, and insights in food formulation will be leveraged to advance the flavor, texture and other attributes of GOOD Meats pipeline of cultivated meat products.
  • Cultivated meat solutions have an exciting role to play in this space, and we are eager to work together with GOOD Meat to bring great-tasting, innovative cultivated meat products to the Singapore market and beyond.

Fujitsu and RIKEN start joint research on next-generation IT drug discovery technology using the supercomputer Fugaku and simulation integrated AI

Retrieved on: 
Tuesday, May 17, 2022 - 3:32am

The joint research project will leverage high performance computing technologies and the supercomputer Fugaku to accelerate simulation integrated AI that combines Fujitsu's DeepTwin AI technology, which accurately acquires quantitative features from complex data by unsupervised learning, with molecular dynamics simulation using RIKEN's AI drug discovery simulation technology.

Key Points: 
  • The joint research project will leverage high performance computing technologies and the supercomputer Fugaku to accelerate simulation integrated AI that combines Fujitsu's DeepTwin AI technology, which accurately acquires quantitative features from complex data by unsupervised learning, with molecular dynamics simulation using RIKEN's AI drug discovery simulation technology.
  • Based on this research, the two parties aim to develop a next-generation IT drug discovery technology with world-leading capabilities by the end of fiscal 2026.
  • RIKEN and Fujitsu will work together to transform the drug discovery process by truly integrating computing technologies such as the supercomputer Fugaku with leading edge AI and machine learning technologies.
  • In this joint research project, Fujitsu and RIKEN will collaborate to develop the world's best computational technology for drug discovery using the world-class supercomputer Fugaku.